Magnetic Field Rotating / MAPK Cancer Research Results

MFrot, Magnetic Field Rotating: Click to Expand ⟱

Features:

Rotary Magnetic field can be generated by a spinning magnet or magnets. Or it can be implemented with 2 or more coils, power with a phase shift between them (90 deg for 2 coil implementation) (60deg for 3 coil implementation)
Targets affected are mostly the same as for Magnet fields
Main differences
- may enhance the EPR effect allowing targeting of drugs to cancer cells
- acts as wireless stirrer, especially on magnetic particles(inducing eddy currents in water media)
- research for use in nano surgery, and mechanical destruction of cancer cells
- continue to highlight ability to raise ROS in cancer cell and lower ROS in normal cells
- RMF may be responsible for Ca2+ distribution to pass across the plasma membrane(differental affected for cancer and normal cells)

Pathways:
- induce ROS production in cancer cells, while decreasing ROS in normal cells. Ca2+ is critical and the Ca2+ balance is increased in cancer cells while decreased in normal cells (example for wound healing)
- ROS↑ related: MMP↓(ΔΨm), Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : TNF-α↓, IL-6↓,
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, MMPs↓, MMP2↓, MMP9↓, IGF-1↓, RhoA↓, NF-κB↓, TGF-β↓, ERK↓
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, ERK↓,
- Others: PI3K↓, AKT↓, Wnt↓, AMPK, ERK↓, JNK,
- Synergies: < Others(review target notes), Neuroprotective, Cognitive,

- Selectivity: Cancer Cells vs Normal Cells

Rotating Magnetic Fields

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	ROS (tumor-selective oxidative stress)	↑ ROS (P→R); sustained to cytotoxicity (G)	↔ minimal change or transient ↑ without injury (P→R)	P, R, G	Primary stress amplifier	Oncomagnetic reports emphasize selective tumor ROS increase with normal-cell sparing in comparable exposure conditions
2	Mitochondrial ETC inhibition (Complex I/NADH:ubiquinone)	↓ Complex I / respiration (P→R)	↔ limited effect (P→R)	P, R	Bioenergetic collapse trigger	Rotating/spinning fields are proposed to disrupt mitochondrial electron flow, driving ROS elevation upstream of ΔΨm loss
3	Ca²⁺ signaling (ER–mitochondria Ca²⁺ transfer / mitochondrial Ca²⁺ load)	↑ Ca²⁺ dysregulation (P→R) contributing to mitochondrial failure (G)	↔ buffered Ca²⁺ homeostasis (P→R)	P, R, G	Amplifies ETC/ROS-driven toxicity	RMF-driven mitochondrial stress can propagate via Ca²⁺ transfer to accelerate ΔΨm loss and pro-death ER stress in tumor cells while sparing normal cells
4	Mitochondrial permeability transition pore (MPTP)	↑ sustained MPTP opening (R→G)	↔ resistant to opening	P, R, G	Mitochondrial point-of-no-return	RMF-enhanced ROS and Ca²⁺ loading promote persistent MPTP opening in tumor mitochondria, driving energetic collapse and apoptosis while normal cells remain below the opening threshold
5	ΔΨm / mitochondrial membrane integrity	↓ ΔΨm (R); progresses (G)	↔ preserved	R, G	Mitochondrial failure threshold	Matches the “energy factory” targeting concept described in Oncomagnetic mechanism narratives
6	GSH depletion	↓ GSH (R→G)	↔ maintained	R, G	Loss of redox buffering	Cancer-selective inability to restore GSH is a key discriminator vs normal cells
7	NRF2 response (selectivity gate)	↔ delayed/insufficient NRF2 (R→G)	↑ NRF2 (R→G)	R, G	Adaptive protection	Normal-cell sparing is consistent with competent NRF2-driven antioxidant defense
8	ER stress / UPR (CHOP commitment)	↑ ER stress (R); CHOP/apoptotic UPR (G)	↑ adaptive UPR (R); resolves (G)	R, G	Proteostasis failure	ETC/ROS stress propagates to ER; commitment vs resolution diverges by cell robustness
9	DNA damage (oxidative; checkpoint markers)	↑ DNA damage (R→G)	↔ or repaired (G)	R, G	Checkpoint stress	Interpreted as ROS-mediated consequence; reported as increased damage markers in some translational datasets
10	LDH / glycolytic vulnerability	↓ LDH performance / ↓ glycolytic flux (R→G)	↔ metabolic flexibility	R, G	Metabolic choke	Cancer glycolysis becomes unstable when NADH/NAD+ and redox buffering are stressed
11	TrxR / thioredoxin system overload	↓ reserve (R→G)	↔ preserved	R, G	Parallel antioxidant collapse	Useful when GSH data are mixed; TrxR can be the limiting system under sustained ROS

Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)

MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.

MAPK, mitogen-activated protein kinase: Click to Expand ⟱

Source: CGL-CS

Type:

Mitogen-activated protein kinases (MAPKs) are a group of proteins involved in transmitting signals from the cell surface to the nucleus, playing a crucial role in various cellular processes, including growth, differentiation, and apoptosis (programmed cell death).

MAPK Pathways: The MAPK family includes several pathways, the most notable being:
1.ERK (Extracellular signal-Regulated Kinase): Often associated with cell proliferation and survival.
2.JNK (c-Jun N-terminal Kinase): Typically involved in stress responses and apoptosis.
3.p38 MAPK: Associated with inflammatory responses and apoptosis.

Inhibitors: Targeting the MAPK pathway has become a strategy in cancer therapy. For example, BRAF inhibitors (like vemurafenib) are used in treating melanoma with BRAF mutations.
Altered Expression Levels:
Overexpression: Many cancers exhibit overexpression of MAPK pathway components, such as RAS, BRAF, and MEK. This overexpression can lead to increased signaling activity, promoting cell proliferation and survival.
Downregulation: In some cases, negative regulators of the MAPK pathway (e.g., MAPK phosphatases) may be downregulated, leading to enhanced MAPK signaling.
The expression levels of MAPK pathway components can serve as biomarkers for cancer diagnosis, prognosis, and treatment response. For example, high levels of phosphorylated ERK (p-ERK) may indicate active MAPK signaling and poor prognosis in certain cancers.

Numerous reports indicate that the MAPK pathway plays a major role in tumor progression and invasion, while inhibition of MAPK signaling reduces invasion.

Scientific Papers found: Click to Expand⟱

204-

MFrot,

MF,

Rotating magnetic field improved cognitive and memory impairments in a sporadic ad model of mice by regulating microglial polarization

in-vivo,

AD,

 0.2T, 4Hz

 reduced aluminum deposition in the brains of AD mice

*NF-kB↓, *MAPK↓, *TLR4↓, *memory↑, *cognitive↑, *TGF-β1↑, *ARG↑, *IL4↑, *IL10↑, *IL6↓, *IL1↓, *TNF-α↓, *iNOS↓, *ROS↓, *NO↓, *MyD88↓, *p‑IKKα↓, *p‑IκB↓, *p‑p65↓, *p‑JNK↓, *p‑p38↓, *ERK↓, *neuroP↑, *Aβ↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Total Targets: 0

Pathway results for Effect on Normal Cells:

Functional Outcomes ⓘ

cognitive↑, 1, memory↑, 1, neuroP↑, 1,
Total Targets: 25

Scientific Paper Hit Count for: MAPK, mitogen-activated protein kinase

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:192  Target#:181  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Magnetic Field Rotating / MAPK Cancer Research Results

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

Cell Death ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Immune & Inflammatory Signaling ⓘ

Protein Aggregation ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Home Page